Cosmos Health Inc. reported record revenue and retired $8 million in senior secured convertible debt more than a year ahead of schedule, while reaffirming its financial guidance for 2026 and beyond.
The company posted second-quarter 2026 revenue of $18.99 million, an increase of 28.8% from the same period a year earlier. First-half revenue totaled $36.91 million, up 29.7% year-over-year. For the full fiscal year 2025, Cosmos Health recorded revenue of $65.27 million, a 20% increase from the prior year. Management reaffirmed guidance for 2026 revenue to exceed $90 million, with a target of $200.6 million by 2029.
On August 28, Cosmos Health completed the full repayment of its $8 million senior secured convertible note issued to ATW in August 2025, which had been due in August 2027. The early retirement eliminates the risk of future conversions tied to that instrument. Total liabilities fell by $6.27 million, or 13.3%, in the first half of 2026, while stockholders' equity rose by 12.2%. The liabilities-to-assets ratio improved by 550 basis points to 66.4% from 71.9% at year-end 2025.
Cosmos Health also repurchased 5.1 million shares for approximately $1.11 million under a $5 million buyback authorization. The company withdrew its Form S-1 and Form S-3 registration statements, leaving no active shelf registration or at-the-market offering program in place.
Product expansion continued with the placement of the C-Scrub brand at Tesco and Superdrug in the United Kingdom. In international markets, Cosmos Health entered Saudi Arabia through a five-year exclusive distribution agreement with Innova Healthcare, which included an initial purchase order for 126,000 units.
Subsidiary Cana Laboratories filed an international patent application for a hydrogel weight management product on June 25, covering the United States, Europe, Australia, and Canada.
